Five percent CO₂ is a potent, fast-acting inhalation anticonvulsant.

Published

Journal Article

CO₂ has been long recognized for its anticonvulsant properties. We aimed to determine whether inhaling 5% CO₂ can be used to suppress seizures in epilepsy patients. The effect of CO₂ on cortical epileptic activity accompanying behavioral seizures was studied in rats and nonhuman primates, and based on these data, preliminary tests were carried out in humans.  In freely moving rats, cortical afterdischarges paralleled by myoclonic convulsions were evoked by sensorimotor cortex stimulation. Five percent CO₂ was applied for 5 min, 3 min before stimulation. In macaque monkeys, hypercarbia was induced by hypoventilation while seizure activity was electrically or chemically evoked in the sensorimotor cortex. Seven patients with drug-resistant partial epilepsy were examined with video-EEG (electroencephalography) and received 5% CO₂ in medical carbogen shortly after electrographic seizure onset.In rats, 5% CO₂ strongly suppressed cortical afterdischarges, by approximately 75%, whereas responses to single-pulse stimulation were reduced by about 15% only. In macaques, increasing pCO₂) from 37 to 44-45 mm Hg (corresponding to inhalation of 5% CO₂ or less) suppressed stimulation-induced cortical afterdischarges by about 70% and single, bicuculline-induced epileptiform spikes by approximately 25%. In a pilot trial carried out in seven patients, a rapid termination of electrographic seizures was seen despite the fact that the application of 5% CO₂ was started after seizure generalization.Five percent CO₂ has a fast and potent anticonvulsant action. The present data suggest that medical carbogen with 5% CO₂ can be used for acute treatment to suppress seizures in epilepsy patients.

Full Text

Duke Authors

Cited Authors

  • Tolner, EA; Hochman, DW; Hassinen, P; Otáhal, J; Gaily, E; Haglund, MM; Kubová, H; Schuchmann, S; Vanhatalo, S; Kaila, K

Published Date

  • January 2011

Published In

Volume / Issue

  • 52 / 1

Start / End Page

  • 104 - 114

PubMed ID

  • 20887367

Pubmed Central ID

  • 20887367

Electronic International Standard Serial Number (EISSN)

  • 1528-1167

International Standard Serial Number (ISSN)

  • 0013-9580

Digital Object Identifier (DOI)

  • 10.1111/j.1528-1167.2010.02731.x

Language

  • eng